Ambys Medicines to Present Data from Universal Human Hepatocyte Program at the 2022 ISSCR Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Ambys Medicines, a company pioneering cell-replacement therapies for patients with liver disease, today announced that data from its universal hepatocyte program will be presented at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting, which will be held June 15-18, 2022, in San Francisco and virtually. Ambys will present proof-of-concept data on its genetically engineered hypoimmunogenic human hepatocytes during an oral session.

“We look forward to presenting data on our universal hepatocyte program that demonstrate the efficient ex vivo genetic engineering of primary human hepatocytes in a metabolic liver disease model using a range of gene editing and delivery technologies,” said Markus Grompe, M.D., Founder and Chief Scientific Officer of Ambys Medicines. “We’re progressing multiple liver cell replacement therapies in development, including our universal human hepatocyte therapy which eliminates the need for immune suppression. These preclinical findings show proof of concept for our engineered hepatocyte replacement approach for severe liver diseases.”

Presentation details follow:

Title: Rescue of a Metabolic Liver Disease Model by Genetically Engineered Hypoimmunogenic Human Hepatocytes
Session: Biotech, Pharma and Academia – Bringing Stem Cells to Patients
Date & Time: Thursday, June 16, 2022, at 6:10 p.m. PT
Room: 2004, Level 2

About Ambys Medicines

Ambys Medicines is focused on pioneering cell replacement therapies for patients with liver failure. Ambys’s proprietary platform enables the company to be the first and only company able to develop and manufacture functional human hepatocytes at scale. Our scientific approach has the potential to fundamentally transform the treatment paradigm for patients with acute and chronic liver failure and genetic diseases of the liver. Our lead program, AMI-918, is a hepatocyte replacement cell therapy in development to restore lost hepatic function. Beyond AMI-918, we are building a pipeline of next-generation modified hepatocytes that will rapidly expand the range of treatable patient populations. Learn more at ambys.com and follow us on Twitter, LinkedIn, and Instagram.